Herukka Sanna-Kaisa, Helisalmi Seppo, Hallikainen Merja, Tervo Susanna, Soininen Hilkka, Pirttilä Tuula
Department of Neuroscience and Neurology, Brain Research Unit, Clinical Research Center, Mediteknia, University of Kuopio, 70211 Kuopio, Finland.
Neurobiol Aging. 2007 Apr;28(4):507-14. doi: 10.1016/j.neurobiolaging.2006.02.001. Epub 2006 Mar 20.
The patients with mild cognitive impairment (MCI) have an elevated risk for Alzheimer's disease (AD). Especially the amnestic MCI is seen as prodrome of AD. Apolipoprotein E (APOE) epsilon4 allele, abnormal CSF Abeta42, Tau and phosphorylated Tau (phospho-Tau) levels are associated with elevated risk for AD.
APOE genotyping was done by PCR based method and baseline CSF Abeta42, Tau and phospho-Tau were measured by ELISA from 60 controls and 79 MCI patients.
Thirty-three MCI patients developed dementia during an average of 3.5 years follow-up. CSF Abeta42 was decreased and Tau and phospho-Tau were increased in the progressive MCI patients. The APOE epsilon4 allele was more frequent in the progressive MCI patients. The APOE epsilon4 allele showed a dose dependent association o the Abeta42 levels in the progressive MCI patients and to all of the markers in controls.
Decreased CSF Abeta42 and elevated Tau or phospho-Tau together with APOE epsilon4 allele are highly predictive for the dementia in MCI patients with amnestic or executive symptoms.
轻度认知障碍（MCI）患者患阿尔茨海默病（AD）的风险升高。尤其是遗忘型MCI被视为AD的前驱症状。载脂蛋白E（APOE）ε4等位基因、脑脊液中异常的β淀粉样蛋白42（Abeta42）、Tau蛋白和磷酸化Tau蛋白（phospho-Tau）水平与AD风险升高相关。
采用基于聚合酶链反应（PCR）的方法进行APOE基因分型，并通过酶联免疫吸附测定（ELISA）法检测60名对照者和79名MCI患者的基线脑脊液Abeta42、Tau蛋白和磷酸化Tau蛋白水平。
在平均3.5年的随访期间，33名MCI患者发展为痴呆。进展性MCI患者的脑脊液Abeta42水平降低，Tau蛋白和磷酸化Tau蛋白水平升高。APOEε4等位基因在进展性MCI患者中更为常见。APOEε4等位基因在进展性MCI患者中与Abeta42水平呈剂量依赖性关联，在对照者中与所有标志物均呈剂量依赖性关联。
脑脊液Abeta42水平降低、Tau蛋白或磷酸化Tau蛋白水平升高以及APOEε4等位基因对有遗忘或执行功能症状的MCI患者发生痴呆具有高度预测性。
